Surge Raises $2.6M, Secures Exclusive Licensing Agreement With Stanford To Make Surgeries Safer
09/23/22, 6:07 PM
Location
san franciscoMoney raised
$2.6 million
Industry
biotechnology
health care
Round Type
seed
Biotech and medical AI innovator Surge announced a $2.6 million round co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley. Veteran angel investors, including Nicolas Godin, the COO/CFO of Cardiologs, also participated in the round. Surge was awarded the 2022 iLab grant, along with other non-dilutive grants to complete the fundraising.
Company Info
Location
san francisco, california, united states
Additional Info
Surge is a biotech company focused on optimizing treatment for patients undergoing surgery. Our multidisciplinary team has developed a test to identify patients at risk for complications. By anticipating surgical risks to enable personalization of the care pathway, this innovation will revolutionize the patient experience and shift the standard of surgical care. Our team shares a common vision for healthcare innovation: to develop patient-focused solutions that benefit the entire healthcare system. https://www.surge.care/